Bausch Health Announces Third Quarter 2025 Financial Results

Bausch Health Companies Inc. reported its third quarter 2025 financial results, highlighting a 7% increase in consolidated revenues to $2.68 billion compared to the prior year period. The company achieved GAAP net income attributable to Bausch Health of $179 million, a significant improvement from a net loss of $85 million in the same quarter of 2024. Adjusted EBITDA attributable to Bausch Health increased by 8% to $986 million, including an $81 million charge for acquired In-Process Research & Development (IPR&D). The company also completed the acquisition of DURECT Corporation, expanding its hepatology portfolio. Bausch Health raised its full-year 2025 revenue and Adjusted EBITDA guidance, reflecting confidence in its continued growth and operational performance.